Affordable Access

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

Authors
Type
Published Article
Journal
AIDS Research and Human Retroviruses
Publisher
Mary Ann Liebert
Volume
14 Suppl 3
Pages
277–289
Source
UCSC Bioinformatics biomedical-ucsc
License
Unknown

Abstract

A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.

Report this publication

Statistics

Seen <100 times